373 results about "Glidant" patented technology

A pharmaceutical composition comprising Compound 1, (R)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide, and at least one excipient selected from: a filler, a diluent, a disintegrant, a surfactant, a glidant and a lubricant, the composition being suitable for oral administration to a patient in need thereof to treat a CFTR mediated disease such as Cystic Fibrosis. Methods for treating a patient in need thereof include administering the pharmaceutical composition of Compound 1 are also disclosed.

Apparatus, process and article for treating an aqueous solution containing a chemical contaminant. The process includes contacting an aqueous solution containing a chemical contaminant with an aggregate composition comprising an insoluble rare earth-containing compound to form a solution depleted of chemical contaminants. The insoluble rare earth-containing compound can include one or more of cerium, lanthanum, or praseodymium. A suitable insoluble cerium-containing compound can be derived from a cerium carbonate, cerium oxalate and/or a cerium salt. The aggregate composition can include more than 10.01% by weight of the insoluble rare earth-containing compound, and in a particular embodiment consists essentially of one or more cerium oxides, and optionally a binder and/or flow aid. Although intended for a variety of fluid treatment applications, such applications specifically include removing or detoxifying chemical contaminants in water.

An aggregate composition and process for making the aggregate composition. The aggregate composition includes an insoluble rare earth-containing compound and a polymer binder. The insoluble rare earth-containing compound can include one or more of cerium, lanthanum, or praseodymium. A suitable insoluble cerium-containing compound can be derived from cerium carbonate or a cerium salt. In a specific embodiment, the aggregate composition consists essentially of one or more cerium oxides, the polymer binder and optionally a flow aid. A process for making the composition includes mixing the insoluble rare earth-containing compound with a polymer binder to form a mixture, and subjecting the mixture to mechanical, chemical and/or thermal treatment to adhere the rare earth compound to the polymer binder. The aggregate composition can be used in a variety of fluid treatment applications to remove one or more chemical and biological contaminants in a fluid.

The invention discloses a gefitinib dispersible tablet, a preparation method and an application thereof. The gefitinib dispersible tablet of the invention comprises the following components by weight: 10-65% of gefitinib, 1-30% of fillers, 10-50% of disintegrants, 1-60% of acidifiers, 0.1-20% of adhesives, and 0.1-30% of lubricants and glidants. According to the invention, gefitinib is wrapped bythe acidifier or gefitinib and the acidifier are wrapped with each other so as to reach the embedding effect. Compared with commercially available common tablets, the gefitinib dispersible tablet of the invention does not contain surfactants, has good dissolvability, dispersibility and disintegrability, and can be disintegrated completely within one minute. The gefitinib dispersible tablet prepared by the method of the invention has a high dissolution rate, good bioavailability, rapid distribution in vivo, and stable quality, and the preparation method is simple and practical, and is applicable to industrial production.

The invention discloses an Apixaban tablet, which comprises the following components in parts: 1 part of Apixaban, 10-20 parts of water-soluble carrier material, 30-60 parts of filling agent, 5-10 parts of disintegrating agent and 5-10 parts of glidant. The Apixaban tablet provided by the invention improves the deficiencies in the prior art that the extracorporeal dissolution rate and the bioavailability is low. The preparation method of the Apixaban tablet disclosed by the invention is simple to operate, has good reproducibility, and is suitable for large-scale production. The Apixaban tablet is mainly used for the anti-thrombosis purpose.

The invention relates to a technical method for producing microfibers by using industrial waste red mud, which comprises the following steps: adding a reactant in the industrial waste red mud to carry out a neutralization reaction; then adding a preparation agent, a glidant and a whitening agent and stirring the agents; after being stirred, feeding materials in a tube-type high-temperature melting furnace continuously; releasing the materials after melting; outputting fused masses continuously to pass through a high-speed roller to carry out centrifugal rejection wire; and splashing a cooling agent and a surface coating agent to produce the red mud microfibers. The production method is suitable for industrial production. The technical method endows the solid waste red mud with the functionality of the microfibers. The technical method can implement various applications, such as pulp production, the preparation of sound and heat insulating materials and energy-saving walling materials, the production of the indoor suspended ceiling of light fire-retardant construction and industrial filtering materials, and the like, and has significant economic value and social meaning.

The present invention relates to a fast disintegrating tablet comprising meloxicam or a pharmaceutically acceptable salt thereof, starch or various starches, glidant and at least one additional excipient.

The invention discloses a dispersible tablet of colloid pectin, which comprises (by weight ratio, in mg) colloid pectine bismuth 25-100 (by bismuth), filling agent 60-400, crumbling agent 42-280, flow aid 1-6, lubricant 0.25-5, the filling agent can be selected from lactose, white dextrine, pregelatine starch or/and starch. The crumbling agent can be selected from cross bonding polyvinylpyrrolidone, crystalline cellulose, cross-linked sodium carboxymethylstarch, low substituted methylcellulose propylene glycol ether, sodium carboxymethylstarch, the glidant can be selected from miropowdered silica gel, the lubricant can be selected from magnesium stearate or/and talcum powder.

The invention provides high-flowability pregelatinized starch and a method for preparing the same by mechanical activation, which belong to the technical field of starch modification processing. The method comprises the following steps: uniformly mixing starch and a certain amount of flow aid in a high-speed mixer uniformly, pre-drying the starch by using heat generated in a high-speed mixing process, and controlling the water content in the starch to be lower than 15 percent; and placing the uniformly mixed materials in a ball mill containing a milling medium, well regulating the temperature for constant-temperature dissolution in water, performing mechanical activation for a certain time period, taking the starch out, and sieving the starch with a 80 to 100-mesh sieve. The method has the advantages of simple process and equipment, small investment, environmentally-friendly process, low production cost, easy product quality control and the like. The prepared product has the characteristics of high flowability, loose structure, uniform particles and precision control over pregelatinization degree and can be widely used in industrials and fields of foods, pharmaceuticals, chemicals and the like.

The invention relates to an orally disintegrating tablet which is prepared by the Chinese medicinal materials of tangerine peel, common yam rhizome, heterophylly falsestarwort root, stir-fried malt and hawthorn fruit; the invention takes the Chinese medicinal materials as raw materials and uses certain proportion of pharmaceutically excipients for the preparation; the invention is prepared by the raw materials with the following weight percentages: 5 to 20 percent traditional Chinese medicine extract, 40 to 80 percent filler, 5 to 30 disintegrating agent, 0.5 to 5 percent flavoring agent, 0.5 to 3 percent glidant and 0.3 to 2 percent lubricant; the disintegrating tablet can be disintegrated in the oral cavity rapidly, the taste is good, so the invention is especially applicable to the elderly people, children and the patients with the difficulty in swallowing for administration.

One of the objects of the invention relates to a pharmaceutical composition in the form of a granulate, wherein the granulates comprises an active pharmaceutical ingredient (API) having a poor water solubility intimately associated with at least one pharmaceutically acceptable sugar, and optionally or preferably at least one pharmaceutically acceptable excipient other than the at least one pharmaceutically acceptable sugar, wherein the active pharmaceutically ingredient has a water solubility less than about 20 mg/ml. The at least one pharmaceutically acceptable excipient other than the at least one pharmaceutically acceptable sugar is selected from the group consisting of disintegrants, wetting agents, diluents, binders, lubricants, glidants, coloring agents and flavoring agents. The at least one pharmaceutically acceptable sugar is preferably selected from pyranosyl pyranoses, such as lactose. Another object of the invention relates to a process for preparing a pharmaceutical granulate, comprising (a) combining an API having poor water solubility with a solution comprising at least one pharmaceutically acceptable sugar, for example a pyranosyl pyranose such as lactose, and a solvent, and optionally at least one pharmaceutically acceptable excipient other than the at least one pharmaceutically acceptable sugar to form a combined mixture; (b) drying the combined mixture of step (a); and (c) comminuting the product of step (b) to obtain the granulate.

The invention relates to a pharmaceutical composition containing mosapride citrate which is applicable to the usage of direct powder compression for preparation and a preparation method thereof. The pharmaceutical composition further contains a disintegrant, a thinner, a lubricant, a glidant and an adhesive in addition to the active component of the mosapride citrate. The pharmaceutical composition is applicable to the preparation of dispersible tablets which can be fully disintegrated in 2 minutes in water under the temperature of 19 DEG C to 21 DEG C and pass through a No. 2 screen, the hardness is 8 to 11Kg, and the dissolution rate is in line with the relevant provisions, thus solving the problems of higher relevant substances, instable quality and difficult packaging of the mosapride citrate dispersible tablets prepared by wet granulation.

One of the objects of the invention relates to a pharmaceutical composition in the form of a granulate, wherein the granulates comprises an active pharmaceutical ingredient (API) having a poor water solubility intimately associated with at least one pharmaceutically acceptable sugar, and optionally or preferably at least one pharmaceutically acceptable excipient other than the at least one pharmaceutically acceptable sugar, wherein the active pharmaceutically ingredient has a water solubility less than about 20 mg/ml. The at least one pharmaceutically acceptable excipient other than the at least one pharmaceutically acceptable sugar is selected from the group consisting of disintegrants, wetting agents, diluents, binders, lubricants, glidants, coloring agents and flavoring agents. The at least one pharmaceutically acceptable sugar is preferably selected from pyranosyl pyranoses, such as lactose. Another object of the invention relates to a process for preparing a pharmaceutical granulate, comprising (a) combining an API having poor water solubility with a solution comprising at least one pharmaceutically acceptable sugar, for example a pyranosyl pyranose such as lactose, and a solvent, and optionally at least one pharmaceutically acceptable excipient other than the at least one pharmaceutically acceptable sugar to form a combined mixture; (b) drying the combined mixture of step (a); and (c) comminuting the product of step (b) to obtain the granulate.

The invention discloses a blonanserin-containing medicinal composition, which consists of the following components in percentage by weight: 3.3 to 20 percent of blonanserin, 60 to 85 percent of filler, 5 to 25 percent of disintegrating agent, 2 to 6 percent of adhesive, 0.25 to 5 percent of lubricant and 0.5 to 2 percent of fluidizer. The medicinal composition has the dissolution rate of over 75 percent in a dissolution medium with the pH of 4.0 to 6.0 so as to effectively solve the problem of dissolution rate of blonanserin medicaments.

The invention provides an oral slow/controlled-release preparation containing febuxostat and a preparation method thereof, which prepare the febuxostat into the long-acting oral slow/controlled-release preparation and can solve the problem that the incidence of an adverse reaction is increased because of the quicker dissolving-out and the burst effect of a common preparation existing in the prior art. The invention has the technical scheme that the oral slow/controlled-release preparation containing the febuxostat comprises the following components by weight percent: 5 to 60 percent of febuxostat, 10 to 50 percent of slow/controlled-release material, 20 to 80 percent of filling auxiliary material, 0.3 to 20 percent of adhesive and 0.1 to 7 percent of lubricant or glidant. Compared with a common quick-release preparation, the slow/controlled-release preparation can keep the effective and stable blood concentration for a longer time, avoids the burst effect of the quick-release preparation, lowers the incidence of the adverse reaction and enhances the application safety.

The invention provides valsartan dispersible tablets and a preparation method thereof, which contain effective doses of valsartan and pharmaceutical adjuvants, which include disintegrants, diluents, binders, lubricants, glidants and surface Active agent, based on 100 parts of valsartan, the dosage of disintegrating agent is 2-50 parts, the dosage of diluent is 10-150 parts, the dosage of binder is 2-25 parts, and the dosage of lubricant is 0.5-20 parts. The dosage of the liquid agent is 0.2-10 parts, and the surfactant is 0.1-2.5 parts; the present invention also provides the preparation method of the valsartan dispersible tablet. Compared with other dosage forms, the valsartan dispersible tablet has a good dispersion state , Short disintegration time, rapid drug dissolution, convenient administration, low production cost, no need for special equipment, convenient and stable carrying and transportation, etc.

The invention relates to a clopidogrel bisulfate tablet and a preparation method thereof. Each clopidogrel bisulfate tablet comprises 25-75 mg of clopidogrel bisulfate measured in the term of clopidogre, fillers, disintegrants, solubilizers, flow aids and lubricants. In the invention, the method of adding granular microcrystalline cellulose and aerosil through airflow crushing disposal to a prescription is adopted, therefore, the process of dry granulating is simple and feasible, reproducibility is good, prepared products have high stability, and the requirement of continuous large-scale production can be satisfied.

The invention relates to a pharmaceutical preparation of mifepristone and preparation method thereof. The pharmaceutical preparation of mifepristone is prepared by the step of mixing the raw materials as follows according to mass ratio: 5-30 % of mifepristone particles, 10-40% of microcrystalline cellulose, 2-10% of adhesive, 20-40% of starch, 20-40% of dextrin, 05.-2% of lubricant, and 0.5-1% of glidant. The invention can improve dissolution and bioavailability of the mifepristone preparation having obviously increased action against early pregnancy of animals, comparatively simple preparation method, and low manufacturing cost.

A granulate for use in a pharmaceutical composition and a pharmaceutical composition manufacture using the granulate, where the granule comprises an active pharmaceutical ingredient (API) having a poor water solubility (i.e., less than about 1 mg/mL) which is intimately associated with at least one pharmaceutically acceptable hydrophilic polymer. The granule optionally contains one or more pharmaceutically acceptable excipients, such as disintegrants, wetting agents, diluents, binders, lubricants, glidants, coloring agents and flavoring agents. The invention also relates to a process for preparing the pharmaceutical granulate and pharmaceutical compositions containing the granulate.

The invention relates to amoxicillin soluble powder and a preparation method thereof. The amoxicillin soluble powder is composed of the following components, by weight: 10-60 parts of amoxicillin trihydrate, 3-20 parts of a cosolvent, 3-30 parts of a stabilizer, 0.4-85 parts of a filler, and 0.05-1 part of a glidant, wherein the stabilizer is sodium hexametaphosphate. The preparation method comprises: micronizing the raw material, amoxicillin trihydrate, crushing and screening the cosolvent, the stabilizer, the filler and the glidant respectively, mixing materials, subpackaging, and checking to obtain the finished amoxicillin soluble powder. The amoxicillin soluble powder is high in solubility and good in stability, can inhibit hydrolysis of drugs and is beneficial to practical application.